Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-8 first-line trifluridine/tipiracil plus panitumumab vs bevacizumab in metastatic colorectal cancer
DRKS00027086Phase 2Recruiting
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic colon cancer (mCRC), colon cancer and rectosigmoid cancer comparing trifluridine/tipiracil + panitumumab with trifluridine/tipiracil + bevacizumab (2 arms). Primary endpoint: Efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab. Started Nov 2021; status: recruiting.
02
Drugs
trifluridine + tipiracilpanitumumabbevacizumab
03
Conditions
metastatic colon cancer (mCRC)colon cancerrectosigmoid cancer
Beyond the preview
Go deeper on DRKS00027086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00027086.